Day: July 11, 2023

Founder of Ridge Partners and Entertainment Industry Veteran brings deep knowledge and experience to the company. Denver, Colorado, July 11, 2023 (GLOBE NEWSWIRE) — Virtual Interactive Technologies Corp., (OTC: VRVR) (“VRVR” or the “Company”), an American multi-platform video gaming developer and publisher, is pleased to announce the addition of Mr. Mark Caplan to its newly expanded board of directors. Mark Caplan is a founder of Ridge Partners, a business development consulting practice providing clients with licensing guidance, advisory, strategic planning, and content distribution strategies across various entertainment media platforms and services. Currently Mark is Vice President Licensing and Games for All Elite Wrestling where he is overseeing the development and launch of their new video game title...

Stan Lee Comics KARTOON STUDIOS ANNOUNCES ‘STAN LEE COMICS’, BASED ON NEVER-BEFORE-RELEASED STORIES AND CHARACTERS CREATED BY STAN LEELegible Kartoon Studios Partners with Powerhouse Publisher Legible for Publication and Distribution of Stan Lee Comics Across Its Broad Digital and Print Platform   Kartoon Studios Partners with Powerhouse Publisher Legible for Publication and Distribution of Stan Lee Comics Across Its Broad Digital and Print Platform BEVERLY HILLS, Calif. and VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) — Kartoon Studios (NYSE AMERICAN: TOON), the controlling partner of “Stan Lee Universe, LLC,” today announced plans for the launch of STAN LEE COMICS, a line of digital and print comic books based on never-before-released stories and characters created by Stan Lee. The Company is partnering...

Only 9% of iStock’s most downloaded sports visuals depict women and girls actively participating in sport. iStock’s VisualGPS research shows 75% of people want to see authentic portrayals of female athletes which emphasize their skill and athleticism, rather than focusing on beauty, glamour, or sex appeal. 8 in 10 people of all genders consider it crucial to provide female athletes with the same level of coverage as their male counterparts.A Media Snippet accompanying this announcement is available at the link below:NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) — As anticipation builds for the upcoming Women’s World Cup, iStock, a leading e-commerce platform providing premium visual content to SMBs, SMEs, creatives and students everywhere, has released research revealing that only 9% of iStock’s most downloaded sports visuals...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated April 26, 2023 to its short form base shelf prospectus dated November 4, 2021 / NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, July 11, 2023 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (NEO:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of the Abaxx Commodity Exchange and Clearinghouse (“Abaxx Singapore”), and producer of the SmarterMarkets™ Podcast, summarizes development activities over the past quarter and the general progress of the Company’s business plans. Highlights:Achieved an important corporate milestone by recognizing first revenues on the...

Jose Rico, CFO, American Rare Earths Jose Rico was appointed the new US-based CFO of American Rare Earths effective July 10.PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) — American Rare Earths (ASX: ARR | OTCQB: ARRNF | FSE:1BHA) (ARR or the Company) is pleased to announce the appointment of Mr. Jose Rico as its new US-based Chief Financial Officer (CFO) who began with the Company effective July 10.Jose has over 22 years of corporate finance and accounting experience across both US domestic and international operations. Prior to joining American Rare Earths, Jose was Global Head of Management Company Finance at Resource Capital Funds, a mining-focused global alternative investment firm, and Managing Director of Corporate Accounting at The Charles Schwab Corporation. Earlier in his career, Jose held various corporate finance and...

Completed Four Investments in Existing Portfolio Companies Representing $50.9 Million in Funded Loans WOODSIDE, Calif., July 11, 2023 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the second quarter ended June 30, 2023. “Runway Growth continues to be disciplined as we prudently expand our portfolio made up of the latest-stage companies in the industries we know best,” said David Spreng, Founder and CEO of Runway Growth. “Our team has maintained a robust pipeline in the first half of 2023 with ample deal flow across all of our key sectors. In parallel, we have been rigorous in our evaluation efforts,...

PALO ALTO, Calif., July 11, 2023 (GLOBE NEWSWIRE) — HP Inc. (“HP”) (NYSE: HPQ) today announced the early tender results as of 5:00 p.m., New York City time, on July 10, 2023 (the “Early Tender Deadline”) for its previously announced cash tender offer (the “Tender Offer”) to purchase up to a combined aggregate purchase price, including the applicable Early Tender Premium (as defined below) but excluding accrued and unpaid interest (the “Purchase Price”), of the notes listed in the table below (collectively, the “Notes,” and each a “Series” of Notes) equal to $1,000,000,000 (the “Maximum Amount”) from each registered holder of the applicable Series of Notes (each, a “Holder,” and collectively, the “Holders”). The Tender Offer will expire at 5:00 p.m., New York City time, on July 25, 2023, unless extended or earlier terminated by...

The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues DFD-29 demonstrated statistical superiority over both Oracea®(doxycycline) capsules and placebo for IGA treatment success in both studies DFD-29 demonstrated statistical superiority over both Oracea® and placebo for the reduction in the total inflammatory lesion count in both studies SCOTTSDALE, Ariz., July 11, 2023 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced positive topline results from the two Phase 3 multicenter, randomized,...

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Brant Binder and Richard Wagner, Ph.D. to its Board of Directors. Concurrently, Charles Cherington and Nicholas Singer have stepped down from the Board. “We are delighted to welcome Brant and Richard to our Board. Both bring a wealth of industry expertise, including founding and leading biotechnology companies with a proven history of delivering value for their stakeholders,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. “We look forward to working together to drive Eterna’s future growth.” Brant Binder is a seasoned...

CHARLOTTESVILLE, Va., July 11, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of AD04, a genetically targeted, serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder (“AUD”), today provided a summary of feedback received following recent meetings with both US and EU regulators, as well as an update on the Company’s current clinical development plan based on guidance received. Feedback from the FDA as well as key country-level regulatory agencies in Europe included:Acknowledgment and confirmation of the importance of ongoing research in the AUD therapeutic area as a persistent high unmet need.    Confirmation of the primary US endpoint based on Percentage of No...